Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or ...
Shares of InMed Pharmaceuticals INM surged 36.33% at market close after the company announced the launch of its neurodegenerative disease program (INM-900 series), to investigate the effects of ...
InMed Pharmaceuticals Inc (NASDAQ:INM) shares are trading higher by 22.6% to $6.05 during Tuesday’s session after the company announced that INM-901 reduced Alzheimer’s-related inflammation in a ...
InMed Pharmaceuticals Inc. (NASDAQ:INM) stock is surging early Tuesday, with a session volume of 6.63 million compared to the average volume of 1.31 million, as per data from Benzinga Pro. On Tuesday, ...
When it comes to treating degenerative diseases like Alzheimer’s, much of the current focus is on addressing the symptoms rather than repairing and regenerating the damaged tissues and cells. Some ...
InMed (NASDAQ: INM) stock rose 300% and change yesterday at one point. INM stock then fell back considerably on the announcement of a stock issue. Which is rather how this world of development pharma ...
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results